Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + everolimus + paclitaxel
- Development stage
- Phase 4
- Lead developer
- Johnson Matthey
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of carboplatin (a platinum-based alkylating agent), everolimus (an mTOR inhibitor), and paclitaxel (a taxane chemotherapy drug). This regimen targets cancer cells through multiple mechanisms: carboplatin forms DNA crosslinks preventing replication, everolimus inhibits the mTOR pathway (specifically mTORC1), and paclitaxel stabilizes microtubules disrupting cell division. The combination has been studied in clinical trials for various cancer types including melanoma, large-cell neuroendocrine carcinoma (LCNEC), and metastatic breast cancer.
- Other names
- everolimus + carboplatin + paclitaxel
02
Targets
DNAMechanistic target of rapamycin complex 1Microtubule
Beyond the preview
Go deeper on carboplatin + everolimus + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + everolimus + paclitaxel.